Poor glycaemic control in Brazilian patients with type 2 diabetes attending the public healthcare system: a cross-sectional study

Luciana V Viana, Cristiane B Leitão, Caroline K Kramer, Alessandra T N Zucati, Deborah L Jezini, João Felício, Ana B Valverde, Antonio R Chacra, Mirela J Azevedo, Jorge L Gross

ABSTRACT

Objectives: To describe the clinical profile of Brazilian patients with type 2 diabetes attending the public healthcare system and identify factors associated with poor glycaemic control.

Setting: Cross-sectional study.

Participants: Patients with type 2 diabetes attending outpatient clinics of the public healthcare system.

Main outcome measured: Glycated haemoglobin (HbA1c), centrally measured by high-performance liquid chromatography (National Glycohemoglobin Standardization Program certified).

Results: A total of 5750 patients aged 61 ± 10 years, with 11 ± 8 years of diabetes duration (66% women, 56% non-white, body mass index: 28.0 ± 5.3 kg/m²) were analysed. Mean HbA1c was 8.6 ± 2.2%, and median HbA1c was 8.1% (6.9% to 9.9%). HbA1c < 7% was observed in only 26% of patients. Mean HbA1c was higher (p < 0.01) in the Northeast (9.0 ± 2.6%) and Northeast (8.9 ± 2.4%) than in the Midwest (8.1 ± 2.1%) and South regions (8.3 ± 1.9%). Using the cut-off value of HbA1c above the median, age (0.986 (0.983 to 0.989)), white ethnicity (0.931 (0.883 to 0.981)) and being from Mid West region (0.858 (0.745 to 0.989)) were protective factors, while diabetes duration (1.015 (1.012 to 1.018)), use of insulin (1.710 (1.624 to 1.802)) and living in the Northeast region (1.197 (1.085 to 1.321)) were associated with HbA1c > 8%.

Conclusions: The majority of Brazilian patients with type 2 diabetes attending the public healthcare system had HbA1c levels above recommended targets. The recognition of Northeast residents and non-white patients as vulnerable populations should guide future policies and actions to prevent and control diabetes.

INTRODUCTION

Brazil is among the 10 countries with the highest prevalence of diabetes mellitus (DM) in the world—about 7.6%. Diabetes is the fifth underlying cause of death in Brazil, affecting 2.5% of the population. Therefore, the aim of this study was to describe the clinical profile of patients with type 2 diabetes receiving public healthcare in the five regions of Brazil and identify factors associated with poor glycaemic control.
PATIENTS
A cross-sectional study was conducted between February 2006 and April 2011 at SUS outpatient clinics with 7201 patients with types 1 and 2 diabetes from the North (n=500; 7%), Northeast (n=2184; 30%), Midwest (n=461; 6%), Southeast (n=3382; 47%) and South (n=674; 9%) regions of Brazil. The number of patients in each region reflects the regional population density as reported in the 2000 national census. A preliminary report describing the characteristics of this patient population, for all regions except the North, has been published. Briefly, the current study was designed to obtain a representative sample of adult patients with type 2 diabetes living in urban areas of Brazil. A total of 14 centres, located in 12 cities belonging to the five regions of our country were included. The included cities were the largest in their respective region and nine of them ranked among the most populous municipalities in Brazil. We also considered that the data would be more reliable if they were collected from public healthcare centres that usually take care of at least 300 patients with diabetes/month. All patients provided written informed consent.

In the present study, we reported the results for 5750 patients with type 2 diabetes for whom HbA1c values were available. Type 2 diabetes was defined as diabetes diagnosed after 30 years of age without insulin use in the first 5 years after the diagnosis. Patients were from the North (n=312; 5%), Northeast (n=1906, 33%), Midwest (n=348, 6%), Southeast (n=2642, 46%) and South (n=542, 9%) regions.

Assessment of clinical characteristics
Information on clinical variables (age, gender, ethnicity, DM duration, body weight, height, physical activity and medications in use,) was obtained by a standardised questionnaire. Ethnicity was self-reported as white or non-white (black, mixed or other—including Asian and Native Brazilians). Marital status was categorised as living with or without a partner, and employment status as working or not currently employed. Educational status was classified as at least 8 years or less than 8 years of formal education. DM treatment was classified as none, diet alone, oral agents, oral agents plus insulin and insulin alone. Frequency of self-blood glucose monitoring (SBGM) and hypoglycaemic episodes in the previous year were recorded. Body mass index (BMI) was calculated (weight/height²; kg/m²). Data were collected in 14 cities representing the five regions of Brazil: South (Porto Alegre, Curitiba), Southeast (São Paulo, Cotia, Campinas, Belo Horizonte, Rio de Janeiro), Midwest (Brasilia, Taguatinga), Northeast (Fortaleza, Recife, Salvador), North (Belém, Manaus).

HbA1c measurements
HbA1c was measured in a central laboratory by an ion-exchange high-performance liquid chromatography method (reference range 4.7–6%) certified by the National Glycohemoglobin Standardization Program and calibrated to the Diabetes Control and Complications Trial standard.

Statistical analyses
The five regions were compared in terms of clinical variables and HbA1c results by one-way analysis of variance (with Bonferroni post hoc test) and χ² tests. The characteristics of patients were evaluated according to glucose control (median HBA1c), region of origin and self-reported ethnic background. Prevalence ratio (PR) and 95% CI were obtained by Poisson regression analyses to determine the association of different factors with HbA1c >8% (dependent variable). Adjustment was made taking into account independent variables selected based on their significance on univariate analyses and/or biological relevance (age, diabetes duration, ethnicity, living with partner, working status, insulin use, SBGM and geographic region).

Variables were expressed as mean±SD, number of cases (%) and median (25–75 IQ intervals). HbA1c was also described as median. Statistical analyses were carried out using SSPS V.18.0. p Values less than 0.05 (two tailed) were considered significant.

RESULTS
A total of 5750 patients with type 2 diabetes were included and the main characteristics were: age of 61±10 years, diabetes duration of 11±8 years and BMI 28.0±5.3 kg/m². Most patients were women (66%), non-white (56%) and lived with a partner (59%). One-third (33%) had completed 8 years of formal education, 20% were employed and 37% were not physically active. Regarding treatment, 1% did not follow any kind of treatment for diabetes, 6% were on diet alone, 57% were taking oral agents, 22% used oral agents and insulin and 13% insulin alone. Mean HbA1c was 8.6±2.2% and median was 8.1% (IQR 6.9–9.9%). HbA1c <7% was found in only 26% of the patients.

Since the majority of the included patients had a poor glycaemic control we decided to compare the characteristic of patients grouped according to median HbA1c (8%). Table 1 describes clinical characteristics and PR (CI 95%) of patients with HbA1c ≥8% and <8%. In unadjusted model, patients with HbA1c ≥8% were younger, non-whites, with longer DM duration, more sedentary, mainly from North and Northeast regions and treated more frequently with insulin than patients with HbA1c <8%. After adjustment, DM duration (1.015 (1.012 to 1.018)), insulin use (1.710 (1.624 to 1.802)) and being from Northeast region (1.197 (1.085 to 1.321)) was associated with HbA1c ≥8%. On the other hand, age (0.986 (0.983 to 0.989)), white ethnicity (0.931 (0.883 to 0.981)) and living in the Midwest region (using the South region as reference; (0.858 (0.745 to 0.989)) were protective factors. In order to further explore the variables associated with HbA1c ≥8% we performed stratified analysis according to geographic region, ethnicity and insulin use. An online
The supplementary table shows unadjusted and adjusted analyses applying the same multivariate model using a cut-off of HbA1c <7%. The differences between the groups of patients with HbA1c <7% and ≥7% did not differ substantially from the results using the cut-off of HbA1c <8%.

The characteristics of the patients stratified by region are described in table 2. Mean HbA1c was higher (p<0.01) in the North (9.0±2.6%) and Northeast (8.9±2.4%) than in the Midwest (8.1±2%), Southeast (8.4±2.1%) and South (8.3±1.9%) regions. Moreover, the five regions differed in all other evaluated characteristics. Patients living in the Northeast had the highest prevalence of non-whites, the lowest BMI and the highest frequency of employed individuals.

Characteristics of patients according to self-reported ethnicity (white and non-white) are described in table 3. Non-white patients had higher HbA1c values, lower BMI and more years of formal education than white patients. They were also younger, more often female and single.

Of the 5750 patients in this study, 35% (2021 patients) used insulin. Of these, 33% (n=658) used insulin once daily, 58% (n=1154) twice daily and 9% (n=189) three times a day or more. Eighty-one per cent (n=1630) of the insulin users performed SBGM, but only 421 (26%) did it on a daily basis. Patients who performed more frequently SBGM had lower values of HbA1c (at least once daily: 9.3±2.1%) than those who did not measure capillary glucose (9.7±2.3%; p=0.008).

**CONCLUSIONS**

In this study, most patients with type 2 diabetes attending the public healthcare system in Brazil had HbA1c levels above the recommended target, that is, above 7%. Being non-white and from the northeast, as well as the longer diabetes duration, and insulin use were factors associated with poor metabolic control, whereas age and being from the Midwest were associated with HbA1c <8% (median HbA1c level for this population). To the best of our knowledge, this is the largest surveillance study to assess glycaemic control in Brazil using a certified method to measure HbA1c. We also may consider that the present study included a representative sample of patients with type 2 diabetes living in the urban areas and attending the public healthcare system in Brazil.

The current survey we chose to use the cut-off value of HbA1c 8% to compare patients with different glycaemic control. The recommended target for HbA1c is below 7%, but it has been recently recommended to individualise the goal of HbA1c. Since only 26% of our patients achieved this target, we adopted a more representative cut-off value (median HbA1c value of our study...
### Table 2

Characteristics of patients with type 2 diabetes according to the five geographic regions of Brazil

<table>
<thead>
<tr>
<th>Region</th>
<th>North</th>
<th>Northeast</th>
<th>Midwest</th>
<th>Southeast</th>
<th>South</th>
<th>P Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>N</td>
<td>312</td>
<td>1906</td>
<td>348</td>
<td>2642</td>
<td>542</td>
<td>—</td>
</tr>
<tr>
<td>HbA1c (%)</td>
<td>9.0±2.6</td>
<td>8.9±2.4</td>
<td>8.1±2.0</td>
<td>8.4±2.1</td>
<td>8.3±1.9</td>
<td>&lt;0.01*</td>
</tr>
<tr>
<td>Age (years)</td>
<td>58±10</td>
<td>61±11</td>
<td>60±11</td>
<td>61±10</td>
<td>62±10</td>
<td>&lt;0.01†,‡</td>
</tr>
<tr>
<td>Diabetes duration (years)</td>
<td>10±8</td>
<td>10±8</td>
<td>11±8</td>
<td>11±9</td>
<td>11±9</td>
<td>0.029</td>
</tr>
<tr>
<td>BMI (kg/m²)</td>
<td>29.0±5.5</td>
<td>27.2±5.0</td>
<td>27.7±5.2</td>
<td>28.2±5.3</td>
<td>29.1±5.3</td>
<td>&lt;0.01†,‡,§,¶</td>
</tr>
<tr>
<td>Females</td>
<td>193 (62)</td>
<td>1317 (69)</td>
<td>245 (70)</td>
<td>1726 (65)</td>
<td>315 (58)</td>
<td>&lt;0.01**</td>
</tr>
<tr>
<td>White</td>
<td>71 (23)</td>
<td>560 (29)</td>
<td>131 (38)</td>
<td>1311 (50)</td>
<td>465 (86)</td>
<td>&lt;0.01**</td>
</tr>
<tr>
<td>Living with a partner</td>
<td>199 (64)</td>
<td>1099 (58)</td>
<td>185 (53)</td>
<td>1537 (58)</td>
<td>355 (66)</td>
<td>&lt;0.01††</td>
</tr>
<tr>
<td>≥8 years of formal education</td>
<td>140 (45)</td>
<td>521 (27)</td>
<td>106 (30)</td>
<td>1011 (38)</td>
<td>122 (27)</td>
<td>&lt;0.01‡‡</td>
</tr>
<tr>
<td>Active worker</td>
<td>112 (36)</td>
<td>341 (18)</td>
<td>65 (19)</td>
<td>482 (18)</td>
<td>136 (25)</td>
<td>&lt;0.01§§</td>
</tr>
<tr>
<td>Sedentary</td>
<td>134 (43)</td>
<td>670 (35)</td>
<td>147 (43)</td>
<td>1005 (38)</td>
<td>168 (31)</td>
<td>&lt;0.01¶¶</td>
</tr>
<tr>
<td>Diabetes treatment</td>
<td>None</td>
<td>2 (1)</td>
<td>18 (1)</td>
<td>7 (2)</td>
<td>38 (1)</td>
<td>6 (1)</td>
</tr>
<tr>
<td></td>
<td>Diet only</td>
<td>14 (5)</td>
<td>145 (8)</td>
<td>31 (9)</td>
<td>138 (5)</td>
<td>15 (3)</td>
</tr>
<tr>
<td></td>
<td>Oral agents</td>
<td>172 (59)</td>
<td>1172 (62)</td>
<td>180 (52)</td>
<td>1426 (54)</td>
<td>345 (64)</td>
</tr>
<tr>
<td></td>
<td>Oral agents and insulin</td>
<td>67 (23)</td>
<td>332 (17)</td>
<td>64 (18)</td>
<td>660 (25)</td>
<td>125 (23)</td>
</tr>
<tr>
<td></td>
<td>Insulin alone</td>
<td>37 (12)</td>
<td>239 (12)</td>
<td>66 (19)</td>
<td>380 (15)</td>
<td>51 (9)</td>
</tr>
</tbody>
</table>

Data are mean±SD or number of patients with the characteristic (%).

*North and Northeast versus Midwest, Southeast and South.
†North versus Northeast, Southeast and South.
‡Midwest and Southeast versus South.
§North versus Northeast and Center-West.
¶Northeast versus Southeast and South.
**Linear-by-linear association.
††Higher in North and South; lower in Midwest.
‡‡Higher in North; lower in Northeast and South.
§§Higher in North and South; lower in Northeast and Southeast.
¶¶Higher in North and Midwest; lower in Northeast and South.

BMI, body mass index.

### Table 3

Demographic and clinical characteristics of patients with type 2 diabetes according to ethnicity

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>White N=2538</th>
<th>Non-white N=3208</th>
<th>P Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>HbA1c (%)</td>
<td>8.3±2.1</td>
<td>8.8±2.3</td>
<td>&lt;0.01</td>
</tr>
<tr>
<td>Age (years)</td>
<td>62±10</td>
<td>60±10</td>
<td>&lt;0.01</td>
</tr>
<tr>
<td>Diabetes duration (years)</td>
<td>11±9</td>
<td>11±8</td>
<td>0.06</td>
</tr>
<tr>
<td>BMI (kg/m²)</td>
<td>28.2±5.2</td>
<td>27.8±5.3</td>
<td>0.003</td>
</tr>
<tr>
<td>Females—n (%)</td>
<td>1615 (64)</td>
<td>2178 (68)</td>
<td>&lt;0.01</td>
</tr>
<tr>
<td>Living with a partner—n (%)</td>
<td>1568 (62)</td>
<td>1805 (56)</td>
<td>&lt;0.01</td>
</tr>
<tr>
<td>At least 8 years of formal education—n (%)</td>
<td>803 (38)</td>
<td>1094 (41)</td>
<td>0.011</td>
</tr>
<tr>
<td>Active worker—n (%)</td>
<td>520 (21)</td>
<td>616 (19)</td>
<td>0.227</td>
</tr>
<tr>
<td>Sedentary—n (%)</td>
<td>904 (36)</td>
<td>1220 (38)</td>
<td>0.072</td>
</tr>
<tr>
<td>Diabetes treatment—n (%)</td>
<td>37 (2)</td>
<td>34 (1)</td>
<td>0.007</td>
</tr>
<tr>
<td>None</td>
<td>151 (6)</td>
<td>192 (6)</td>
<td></td>
</tr>
<tr>
<td>Diet only</td>
<td>1498 (59)</td>
<td>1794 (22)</td>
<td></td>
</tr>
<tr>
<td>Oral agents</td>
<td>533 (21)</td>
<td>714 (22)</td>
<td></td>
</tr>
<tr>
<td>Oral agents and insulin</td>
<td>314 (12)</td>
<td>459 (15)</td>
<td></td>
</tr>
<tr>
<td>Geographic region—n (%)</td>
<td></td>
<td></td>
<td>&lt;0.01</td>
</tr>
<tr>
<td>North</td>
<td>71 (23)</td>
<td>241 (77)</td>
<td></td>
</tr>
<tr>
<td>Northeast</td>
<td>560 (29)</td>
<td>1344 (71)</td>
<td></td>
</tr>
<tr>
<td>Midwest</td>
<td>131 (38)</td>
<td>217 (62)</td>
<td></td>
</tr>
<tr>
<td>Southeast</td>
<td>1311 (50)</td>
<td>1329 (50)</td>
<td></td>
</tr>
<tr>
<td>South</td>
<td>465 (86)</td>
<td>77 (14)</td>
<td></td>
</tr>
</tbody>
</table>

Data are mean±SD, number of patients with the characteristic.

BMI, body mass index; HbA1c, glycated haemoglobin.
Diabetes control varies in different countries. In the USA, mean HbA1c among middle-aged adults was approximately 7.3%. Patients with type 2 diabetes using oral agents to treat diabetes in seven European countries had similar glycaemic control (mean HbA1c 7.2%). However, in the EURIKA study, a performance study in 12 European countries, only 36.7% of patients with type 2 diabetes achieved the goal of HbA1c <6.5%. In the present study, mean HbA1c (8.6±2.2%) was much higher than that observed in these countries, and only 26% of our patients had HbA1c below the 7% goal.

In our study, a broad range of HbA1c levels were also observed across Brazilian regions. The poor glycaemic control observed in the Northeast than the other regions might be explained by a diverse ethnic and economic background. Numerous studies show ethnic disparities in HbA1c values, a meta-analysis has reported that African-Americans had absolute HbA1c values 0.65% higher than non-Hispanic whites. According to the Brazilian Geography and Statistics Institute, 23.6% of the population in the North and 28.9% in Northeast are white, versus 41.7% in the Midwest, 56.7% in the Southeast and 78.5% in the South. In our study, the difference in HbA1c between whites and non-whites was about 0.5%. Regarding the role of economic status, per capita income is almost twice as high in the South than in the Northeast. In this sense, a European surveillance of socioeconomic predictors of mortality has demonstrated an association between low income and higher mortality in men with type 2 diabetes.

Free, universal healthcare has been available to all Brazilian citizens since 1988, including free access to many drugs. Metformin, sulfonylureas and insulin are distributed in primary care units and drugstores around the country. However, other medications used to treat diabetes are not covered. Also, SBGM devices are not freely supplied. Therefore, although our Public Health System may represent an advance in healthcare, it has not been enough to reach glycaemic control targets in diabetes care. Other measures are highly necessary, and should include a structured diabetes education programme, public policies to improve adherence to diet and exercise, and free access to SBGM, at least to all patients on insulin.

The present study has limitations. First, surveillance was based on self-reported answers, although medical records were consulted when available. Second, only patients attending the public healthcare system were evaluated and it is known that almost one-fourth of the Brazilian population rely on private healthcare. Finally, due to its cross-sectional design, our study was able to identify associations between several factors and glycaemic control, but was unable to pinpoint risk factors. It is also important to remember that reverse causality is always possible in cross-sectional studies, and poor glycaemic control in patients using insulin cannot be attributed to insulin prescription per se. As insulin is generally prescribed to patients with more severe diabetes, the health status of these patients may also account for their poor glycaemic control. We may consider that only patients with diabetes living in urban areas could represent a potential limitation. However we can speculate that patients from the rural areas of our country, who attend primary care units less equipped and with less trained healthcare personnel, may have even poorer diabetes control.

In conclusion, Brazilian patients with type 2 diabetes attending the public healthcare system have poor glycaemic control as demonstrated by HbA1c values far above the recommended target. New strategies are necessary to improve glycaemic control in this population. Furthermore, the increased vulnerability of Northeast residents and non-white patients to poor metabolic control should be taken into account when designing strategies to control diabetes.

Contributors LVV and CBL were responsible for the logistics of data and blood sample collections in the North and Northeast, analyses of data and writing the manuscript, CKK analysed data, ATNZ worked as a research assistant, DLJ collected the data and blood samples in the North, JF collected the data and blood samples in the Northeast, ABV and ARC were responsible for the data and blood sample collections in the Southeast and Midwest, MJA and JLG were responsible for the data collection in the South, idealising and reviewing the manuscript.

Funding Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq), Fundo de Incentivo À Pesquisa (FiPE) of Hospital de Clínicas de Porto Alegre (HCPA) and Pfizer Pharmaceutical.

Competing interests None.

Patient consent Obtained.

Ethics approval The protocol was approved by the Ethics Committee at Hospital de Clínicas de Porto Alegre and at each participating centre/clinic.

Provenance and peer review Not commissioned; externally peer reviewed.

Data sharing statement No additional data are available.

Open Access This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 3.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/3.0/

REFERENCES


14. http://www.todospelaeducacao.org.br/educacao-no-brasil/busa-comparativa/resultado/resultado/?tipo=1&id_check_universo%5B%5D=10905&id_universo%5B%5D=10905&check_universo%5B%5D=%D10902&id_universo%5B%5D=10902&id_check_universo%5B%5D=10901&id_universo%5B%5D=10901&check_universo%5B%5D=10903&check_universo%5B%5D=10903&check_universo%5B%5D=10904&check_universo%5B%5D=10904&check_universo%5B%5D=157&check_universo%5B%5D=157&check_universo%5B%5D=157&comparar=Comparar (accessed Feb 2012).


Poor glycaemic control in Brazilian patients with type 2 diabetes attending the public healthcare system: a cross-sectional study

Luciana V Viana, Cristiane B Leitão, Caroline K Kramer, Alessandra T N Zucatti, Deborah L Jezini, João Felicio, Ana B Valverde, Antonio R Chacra, Mirela J Azevedo and Jorge L Gross

BMJ Open 2013 3:
doi: 10.1136/bmjopen-2013-003336

Updated information and services can be found at:
http://bmjopen.bmj.com/content/3/9/e003336

These include:

Supplementary Material
Supplementary material can be found at:
http://bmjopen.bmj.com/content/suppl/2013/09/18/bmjopen-2013-003336.DC1

References
This article cites 11 articles, 4 of which you can access for free at:
http://bmjopen.bmj.com/content/3/9/e003336#BIBL

Open Access
This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 3.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/3.0/

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Topic Collections
Articles on similar topics can be found in the following collections
Diabetes and Endocrinology (415)

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/